{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:42:06Z","timestamp":1793292126814,"version":"4.5.0"},"reference-count":52,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.2967\/jnumed.123.265763","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:06:37Z","timestamp":1698750397000},"page":"1779-1787","source":"Crossref","is-referenced-by-count":29,"title":["Lesion Dosimetry for [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Milan","family":"Grkovski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"ODonoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Andl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lafontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmin","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Thor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Humm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"2026020205350923000_64.11.1779.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"2026020205350923000_64.11.1779.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"2026020205350923000_64.11.1779.3","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol."},{"key":"2026020205350923000_64.11.1779.4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/COC.0000000000000169","article-title":"Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists","volume":"40","author":"Lewis","year":"2017","journal-title":"Am J Clin Oncol."},{"key":"2026020205350923000_64.11.1779.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.175"},{"key":"2026020205350923000_64.11.1779.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.004"},{"key":"2026020205350923000_64.11.1779.7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography","volume":"1","author":"Kneebone","year":"2018","journal-title":"Eur Urol Oncol."},{"key":"2026020205350923000_64.11.1779.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026020205350923000_64.11.1779.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4298"},{"key":"2026020205350923000_64.11.1779.10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","article-title":"Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350923000_64.11.1779.11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nucmedbio.2021.05.001","article-title":"Combination radionuclide therapy: a new paradigm","volume":"9899","author":"Suman","year":"2021","journal-title":"Nucl Med Biol."},{"key":"2026020205350923000_64.11.1779.12","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted radionuclide therapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet Oncol."},{"key":"2026020205350923000_64.11.1779.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.12.031"},{"key":"2026020205350923000_64.11.1779.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2021","journal-title":"J ICRU."},{"key":"2026020205350923000_64.11.1779.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.08.022"},{"key":"2026020205350923000_64.11.1779.16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","article-title":"Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment nave patients, phase I study (PROQURE-I trial)","volume":"23","author":"van der Sar","year":"2023","journal-title":"BMC Cancer."},{"key":"2026020205350923000_64.11.1779.17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bju.15988","article-title":"LUNAR: a randomized phase 2 study of 177lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)","volume":"132","author":"Ma","year":"2023","journal-title":"BJU Int."},{"key":"2026020205350923000_64.11.1779.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219501"},{"key":"2026020205350923000_64.11.1779.19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"2026020205350923000_64.11.1779.20","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.3390\/cancers13194982","article-title":"Oligometastatic disease detection with 68Ga-PSMA-11 PET\/CT in hormone-sensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical impact","volume":"13","author":"Artigas","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026020205350923000_64.11.1779.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0866-0"},{"key":"2026020205350923000_64.11.1779.22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11307-021-01670-5","article-title":"A pilot study of dynamic 18F-DCFPyL PET\/CT imaging of prostate adenocarcinoma in high-risk primary prostate cancer patients","volume":"24","author":"Lu","year":"2022","journal-title":"Mol Imaging Biol."},{"key":"2026020205350923000_64.11.1779.23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies","volume":"73","author":"Rowe","year":"2018","journal-title":"Eur Urol."},{"key":"2026020205350923000_64.11.1779.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.211094"},{"key":"2026020205350923000_64.11.1779.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263738"},{"key":"2026020205350923000_64.11.1779.26","doi-asserted-by":"crossref","first-page":"145017","DOI":"10.1088\/1361-6560\/ab2a22","article-title":"Performance evaluation of quantitative SPECT\/CT using NEMA NU 2 PET methodology","volume":"64","author":"Ryu","year":"2019","journal-title":"Phys Med Biol."},{"key":"2026020205350923000_64.11.1779.27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40658-020-0278-3","article-title":"Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT\/CT systems","volume":"7","author":"Peters","year":"2020","journal-title":"EJNMMI Phys."},{"key":"2026020205350923000_64.11.1779.28","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1002\/mp.12586","article-title":"Voxel-based multimodel fitting method for modeling time activity curves in SPECT images","volume":"44","author":"Sarrut","year":"2017","journal-title":"Med Phys."},{"key":"2026020205350923000_64.11.1779.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"2026020205350923000_64.11.1779.30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40658-022-00512-9","article-title":"Quantification and dosimetry of small volumes including associated uncertainty estimation","volume":"9","author":"Carnegie-Peake","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2026020205350923000_64.11.1779.31","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","article-title":"Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer","volume":"50","author":"Mader","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350923000_64.11.1779.32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2022.08.035","article-title":"Failure patterns by PSMA PET for recurrent prostate cancer after prostatectomy and salvage radiation","volume":"170","author":"Imber","year":"2022","journal-title":"Urology."},{"key":"2026020205350923000_64.11.1779.33","first-page":"1","article-title":"Radiobiology of systemic radiation therapy","volume":"22","author":"Murray","year":"2007","journal-title":"Cancer Biother Radiopharm."},{"key":"2026020205350923000_64.11.1779.34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","volume":"110","author":"Zelefsky","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026020205350923000_64.11.1779.35","doi-asserted-by":"crossref","first-page":"100864","DOI":"10.1016\/j.adro.2021.100864","article-title":"Positron emission tomography-derived metrics predict the probability of local relapse after oligometastasis-directed ablative radiation therapy","volume":"7","author":"Greco","year":"2021","journal-title":"Adv Radiat Oncol."},{"key":"2026020205350923000_64.11.1779.36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2026020205350923000_64.11.1779.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2026020205350923000_64.11.1779.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178483"},{"key":"2026020205350923000_64.11.1779.39","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","article-title":"EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations","volume":"45","author":"Gear","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350923000_64.11.1779.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262782"},{"key":"2026020205350923000_64.11.1779.41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40644-022-00475-1","article-title":"Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET\/MRI and 68Ga-PSMA-11 PET\/MRI","volume":"22","author":"Zhang","year":"2022","journal-title":"Cancer Imaging."},{"key":"2026020205350923000_64.11.1779.42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/mp.12124","article-title":"Classification and evaluation strategies of auto-segmentation approaches for PET: report of AAPM task group no. 211","volume":"44","author":"Hatt","year":"2017","journal-title":"Med Phys."},{"key":"2026020205350923000_64.11.1779.43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264916"},{"key":"2026020205350923000_64.11.1779.44","first-page":"44","article-title":"Partial volume effect in SPECT & PET imaging and impact on radionuclide dosimetry estimates","volume":"11","author":"Marquis","year":"2023","journal-title":"Asia Ocean J Nucl Med Biol."},{"key":"2026020205350923000_64.11.1779.45","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a doseeffect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"J Nucl Med."},{"key":"2026020205350923000_64.11.1779.46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.053173"},{"key":"2026020205350923000_64.11.1779.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2008.04.004"},{"key":"2026020205350923000_64.11.1779.48","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/aaf26a"},{"key":"2026020205350923000_64.11.1779.49","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1172\/JCI97631","article-title":"Single-dose radiotherapy disables tumor cell homologous recombination via ischemia\/reperfusion injury","volume":"129","author":"Bodo","year":"2019","journal-title":"J Clin Invest."},{"key":"2026020205350923000_64.11.1779.50","doi-asserted-by":"publisher","DOI":"10.1118\/1.2836421"},{"key":"2026020205350923000_64.11.1779.51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13014-022-02010-9","article-title":"Variability of a\/ ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy","volume":"17","author":"Cui","year":"2022","journal-title":"Radiat Oncol."},{"key":"2026020205350923000_64.11.1779.52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262750"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:19:31Z","timestamp":1785269971000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.2967\/jnumed.123.265763"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265763","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}